Efficacy of Bioactive Glass vs. Xenograft in Maxillary Sinus Augmentation
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-65
SponsorSuez Canal University
About this trial
This randomized controlled study aims to evaluate the clinical, radiographic, and histologic efficacy of using bioactive glass bone graft (UNIGRAFT by Biomed Inc., USA) compared to a conventional xenograft in maxillary sinus augmentation procedures. A total of 20 patients classified as SA4 according to the Misch classification will be enrolled and randomly allocated into two groups. Outcomes will be assessed using Cone Beam Computed Tomography (CBCT) for vertical bone gain and, where applicable, histologic analysis. The study is conducted at the Faculty of Dentistry, Suez Canal University.
Eligibility criteria
Qualifiers
Patients requiring maxillary sinus floor augmentation for dental implant placement.
Residual alveolar bone height ≤ 4 mm in posterior maxilla (SA4 classification).
Age between 20 to 65 years.
Good general health and able to attend scheduled follow-up visits.
Disqualifiers
Presence of systemic conditions that could affect bone healing (e.g., uncontrolled diabetes, osteoporosis).
Heavy smoking (more than 10 cigarettes/day).
Active sinus pathology or previous sinus surgery.
Pregnant or breastfeeding women.
Trial design
Treatments tested in this trial
- Bioactive Glass Bone Graft (UNIGRAFT)
- Xenograft Bone Graft (Bio-Oss)
Treatment groups
20 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov